Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders
10.10.2024 16:17:00 CEST | Business Wire | Press release
Offering empowers OEM's and ISV’s to develop products up to 3X faster and reduce costs of ownership by 80%
Cognite,the Data and AI authority for industry, today announced the launch of Cognite Embedded. This new offering enables Original Equipment Manufacturers (OEMs) and Industrial Software Vendors (ISVs) to accelerate time to market, drastically reduce total cost of ownership, and future-proof their digital solutions with AI-ready architectures, all through Cognite’s leading industrial data platform, Cognite Data Fusion, and low-code industrial agent workbench, Cognite Atlas AI ®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009752580/en/

Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders (Photo: Business Wire)
Integrating and contextualizing data is often the biggest hurdle for OEMs and ISVs. Additionally, they need to onboard new customers and roll out data-driven solutions without the high costs associated with maintaining complex custom infrastructures.
Cognite Embedded empowers OEMs and ISVs to accelerate product development by 2-3x and reduce their total cost of ownership by up to 80% by leveraging Cognite Data Fusion’s powerful industrial data modeling features, unique contextualization capabilities that address both structured and unstructured industrial data, and built-in scalability.
Cognite Atlas AI makes it easier to integrate Industrial AI agents into products and solutions for industrial use cases like predictive maintenance and real-time operational optimization, allowing OEMs and ISVs to future-proof their architectures and end-user interfaces.
"By building on Cognite Data Fusion, we've been able to bring our solutions to market at lightning speed," said Arvind Rao, VP Industry Solutions, Data & Analytics, Rockwell Automation. “Partnering with Cognite to develop our FactoryTalk DataMosaix platform has streamlined our development process, allowing us to focus on delivering value to our customers while cutting our time to market significantly. We’re now delivering advanced digital solutions like Energy Management, leveraging Cognite Data Fusion, faster than ever before."
"Cognite's platform has enabled us to seamlessly integrate our offering for reliability- Newton into our customers' systems," said Mark Felder, CTO of Pinnacle Reliability. "Cognite Data Fusion has empowered our services teams to quickly deploy new tools, reports, and data analytics, allowing them to focus on delivery and integration independently from our development teams, which enables us to concentrate on new innovations and bring value to our customers more quickly."
"Partnering with Cognite has empowered us to unlock and utilize data from production operations, fundamentally transforming how we fuel AI and deliver value to our customers through our Lumi platform," said Shashi Menon, VP of Digital Development at SLB. "The scalability and adaptability of Cognite Data Fusion equips us to help our customers harness their production data, optimizing operations through our OptiSite and OptiFlow solutions.”
“The launch of Cognite Embeddedis a testament to Cognite’s commitment to enabling OEMs and ISVs to build and scale the next generation of industrial solutions,” said Girish Rishi, CEO, Cognite. "With Cognite Embedded, equipment and software builders and developers can focus on delivering cutting-edge products without the typical data complexities that slow down innovation. Our platform offers speed, scalability, and the flexibility to integrate AI in a way that future-proofs their solutions for years to come."
The Cognite Embedded offering includes the Embedded Team, a dedicated partner service that will help OEMs and ISVs leverage industrial data for greater efficiency, smarter decision-making, and sustained innovation.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009752580/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom